Literature DB >> 18592242

[Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options].

C G Hammerschmied1, B Walter, A Hartmann.   

Abstract

By integrating genetic data into the traditional histology and immunohistochemistry-based classification system the revised WHO-classification of malignant tumours (2004) defined additional renal cell carcinoma subtypes, thereby enabling the application of additional diagnostic procedures. Therapy for advanced clear cell renal cell carcinoma has also seen significant progress. This report focuses on these developments, pinpoints current obstacles and provides future prospects.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18592242     DOI： 10.1007/s00292-008-1011-5

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  40 in total

1.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Authors:  Mark J Ratain; Tim Eisen; Walter M Stadler; Keith T Flaherty; Stan B Kaye; Gary L Rosner; Martin Gore; Apurva A Desai; Amita Patnaik; Henry Q Xiong; Eric Rowinsky; James L Abbruzzese; Chenghua Xia; Ronit Simantov; Brian Schwartz; Peter J O'Dwyer
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

Review 2.  Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials.

Authors:  John S Lam; Allan J Pantuck; Arie S Belldegrun; Robert A Figlin
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

3.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.

Authors:  B Escudier; C Chevreau; C Lasset; J Y Douillard; A Ravaud; M Fabbro; A Caty; J F Rossi; P Viens; J P Bergerat; J Savary; S Négrier
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

Review 6.  Renal cell carcinoma: current status and emerging therapies.

Authors:  Eric C Nelson; Christopher P Evans; Primo N Lara
Journal:  Cancer Treat Rev       Date:  2007-02-27       Impact factor: 12.111

7.  Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Authors:  Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 8.  Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.

Authors:  Luciano J Costa; Harry A Drabkin
Journal:  Oncologist       Date:  2007-12

9.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

Review 10.  Targeted therapy for metastatic renal cell carcinoma.

Authors:  P H Patel; R S K Chaganti; R J Motzer
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640
View more
  4 in total

1.  [Histopathology of renal cell carcinoma].

Authors:  C G Stöhr; K Amann; A Hartmann
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

2.  Cell-based quantification of molecular biomarkers in histopathology specimens.

Authors:  Yousef Al-Kofahi; Wiem Lassoued; Kedar Grama; Sumit K Nath; Jianliang Zhu; Ridha Oueslati; Michael Feldman; William M F Lee; Badrinath Roysam
Journal:  Histopathology       Date:  2011-07       Impact factor: 5.087

Review 3.  [Renal cell carcinomas. Pathomorphologic diagnosis in the light of modern pharmacotherapy].

Authors:  S Störkel
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

Review 4.  Distribution of glucose transporters in renal diseases.

Authors:  Leszek Szablewski
Journal:  J Biomed Sci       Date:  2017-08-31       Impact factor: 8.410
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.